中新网北京1月18日电(张国清 陈建)全军肿瘤中心、全军骨髓移植中心——解放军307医院采用“微移植”的方法治疗白血病，使患者6年生存率达80%以上，这比传统疗法高20多个百分点。由于“微移植”疗法可以免去放疗、减少化疗，这使白血病患者的免疫系统受损较小，进而降低了感染、罹患肺炎等并发症的风险，治疗费用仅相当于目前普遍采用的传统疗法的三分之一。

Beijing Beijing January and report(ZhangGuoQing ChenJian)Army cancer center,/Army a bone marrow transplant center - the people's liberation army 307 hospital use"Micro transplantation"Treatment of leukemia,Make patients 6 years survival rate of more than 80%,This is the traditional therapy high more than.because"Micro transplantation"Radiation therapy can free/Reduce chemotherapy,The leukemia patients' immune system is damaged,And then reduce the infection/Suffering from pneumonia and the risk of complications,Treatment costs only equivalent to the current widespread use of the traditional therapy of a third.

　　专家介绍，在白血病患者中，中青年发病率达70%左右。目前，国内对中青年急性髓性白血病缓解后的治疗，一直采用化疗或造血干细胞移植等传统方法，化疗治愈比例不到40%；移植治愈率虽然可达70%左右。但这种移植的前提是需要找到配型完全相合的供者。由于寻找完全相合的供者相当困难，能做这种移植的幸运者很少，而且移植后引起的严重感染和相关并发症高达70%以上。

Expert introduction,In leukemia patients,Young and middle-aged incidence was 70%.At present,In young and middle-aged acute myelogenous leukemia ease after the treatment,Has been chemotherapy or hematopoietic stem cell transplantation and other conventional methods,Chemotherapy cure ratio less than 40%;Although graft rate can reach 70%.But this kind of transplantation is the premise of need to find type-specific fit like a glove donor.Because looking for fit like a glove donor is quite difficult,Can do the transplant the few,After transplantation and cause serious infection and related complications as high as 70% above.

　　从2003年开始，解放军307医院全军血液病研究所所长艾辉胜带领团队，对白血病进行了系统的微移植试验和临床研究。微移植是在非清髓移植的基础上创新发展的新技术，被称为是治疗白血病的一次“革命”。

Starting from 2003,The people's liberation army 307 hospital army blood institute director YiHuiSheng lead the team,The system of leukemia micro transplantation test and clinical research.Micro transplantation in nonmyeloablative transplantation is the basis of the innovation and development of new technology,Is known as a treatment for leukemia"revolution".

　　艾辉胜团队先后对101例中青年急性髓性白血病缓解后的患者采用微移植方法治疗，获得前所未有的成功。通过长期观察随访，证实6年无病生存率及总生存率分别为84.4%、89.5%。这一结果比目前普遍采用的传统化疗和干细胞移植的生存率、治愈率高20多个百分点。

YiHuiSheng team successively in 101 cases of young and middle-aged acute myelogenous leukemia patients relieve the micro transplantation treatment method,The unprecedented success of the gain.Through the long-term follow-up observation,Confirm 6 years disease-free survival and overall survival rate was 84.4%/89.5%.The results than the current widespread use of the traditional chemotherapy and stem cell transplantation survival rate/High cure rate more than.

　　其研究论文“微移植：中青年急性髓性白血病缓解后治疗”于2012年11月发表在美国权威期刊《临床肿瘤学杂志》上。此论文为我国血液病学者在该期刊上首次发表，引起了国际权威专家的高度评价，称微移植是“分离移植物抗肿瘤效应和移植物抗宿主病的新模式”。这项研究也获得了国家自然科学基金重点课题资助。

The research paper"Micro transplantation:Young and middle-aged acute myelogenous leukemia after relief treatment"In November of 2012 published in the American journal of authority[The journal of clinical oncology]on.This paper for our country hematonosis scholars in this journal published for the first time,By the international authoritative expert is highly evaluated,Says micro transplantation is"Separation graft-versus-tumor effects and graft versus host disease of the new model".The study also won the national natural science foundation in key project funding.

　　在今天下午举行的新闻协调会上，艾辉胜介绍，与传统的造血干细胞移植完全不同，“微移植”既具备抗白血病作用强、造血功能恢复快的优点，又巧妙避免了传统移植的排异性难题。传统移植要在术前对患者进行大剂量“致死性”预处理，大量杀死健康细胞，有时甚至可能影响青少年的生长发育和成年患者的生殖能力。

In today's afternoon news conference held coordination,YiHuiSheng introduced,With the traditional hematopoietic stem cell transplantation is totally different,"Micro transplantation"Both have strong resistance to leukemia effect/Hematopoietic function restore fast advantages,Clever and avoid the traditional transplantation PaiYiXing problem.In traditional transplantation for patients with preoperative high-dose"deadly"pretreatment,A large number of kill healthy cells,Sometimes even may affect the growth and development of adolescents and adults with reproductive ability.

　　但微移植患者无需这种预处理，仅在针对肿瘤的微量化疗后，输入激活的健康供者造血干细胞。数个疗程后，形成供者细胞微嵌合植入，既能不断清除体内残留的白血病细胞，又能激活患者自身免疫系统，达到最终治愈白血病的目的。

But micro transplant patients without the pretreatment,Only in the tumor trace after chemotherapy,Input active healthy donor hematopoietic stem cells.Number after a period of treatment,Formation of donor cell micro Mosaic implant,Can constantly removes residual leukemia cells,And can activate the patient's own immune system,To achieve the purpose of the final cure leukemia.

　　他说，微移植非常安全简便，在国内、国外的普通医院中均可实施。由于“微移植”可以免去针对白血病患者的放疗，减少化疗，从而使患者的免疫系统受损较小，进而降低了感染、罹患肺炎等并发症的风险。综合而言，新疗法的费用仅相当于目前普遍采用的传统疗法的三分之一。更可喜的是，“微移植”不受病人年龄和配型限制，小到儿童，大80岁以上老人都可耐受。无论家族成员，还是无关不相合人员，均可作为微移植的供者。(完)

He said,Micro transplantation is very safe,In China/Foreign general hospital all can implement.because"Micro transplantation"Can be free for leukemia patients with radiation,Reduce chemotherapy,So as to make a patient's immune system is damaged,And then reduce the infection/Suffering from pneumonia and the risk of complications.altogether,The cost of a new therapy is only equivalent to the current widespread use of the traditional therapy of a third.More delightful is,"Micro transplantation"From the patient age and limit matches,Small children to,80 years old man can tolerate.Whether family members,Still not out of keeping with personnel,All can be used as micro transplantation donor.(finish)